NCT03497689 - EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Intravenous/Subcutaneous Treprostinil; Oral Treprostinil

Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)

Trial Locations (11)

15213

UPMC Presbytarian Hospital, Pittsburgh

30106

Piedmont Healthcare Pulmonary and Critical Care Research, Austell

32803

Florida Hospital, Orlando

43210

The Ohio State University Wexner Medical Center, Columbus

45267

University of Cincinnati Health, Cincinnati

46260

St. Vincent Medical Group, Indianapolis

68198

University of Nebraska Medical Center, Omaha

73112

Integris Baptist Medical Center, Oklahoma City

87131

University of New Mexico Health Sciences Center, Albuquerque

90502

Harbor-UCLA Medical Center, Torrance

93701

University of California San Francisco - Fresno, Fresno